Content-Length: 559796 | pFad | https://link.springer.com/10.1007/s11033-024-09680-6

86400 Understanding the HPV associated cancers: A comprehensive review | Molecular Biology Reports Skip to main content

Advertisement

Springer Nature Link
Log in

Understanding the HPV associated cancers: A comprehensive review

  • Review
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Human papillomavirus (HPV), a common cause of sexually transmitted diseases, may cause warts and lead to various types of cancers, which makes it important to understand the risk factors associated with it. HPV is the leading risk factor and plays a crucial role in the progression of cervical cancer. Viral oncoproteins E6 and E7 play a pivotal role in this process. Beyond cervical cancer, HPV-associated cancers of the mouth and throat are also increasing. HPV can also contribute to other malignancies like penile, vulvar, and vaginal cancers. Emerging evidence links HPV to these cancers. Research on the oncogenic effect of HPV is still ongoing and explorations of screening techniques, vaccination, immunotherapy and targeted therapeutics are all in progress. The present review offers valuable insight into the current understanding of the role of HPV in cancer and its potential implications for treatment and prevention in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

No datasets were generated or analysed during the current study.

References

  1. Deniz Z, Uraz S, Holem R, Ozaras R, Tahan V (2022) Human Papillomavirus Infection and Oropharyngeal and Gastrointestinal Cancers: A Causal Relationship?Diseases, 10(4), 94

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249

    Google Scholar 

  3. Kori M, Arga KY (2022) Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics. Expert Rev Anticancer Ther 22(11):1211–1224

    CAS  PubMed  Google Scholar 

  4. Bogani G, Martinelli F, Ditto A, Taverna F, Lombardo C, Signorelli M, Raspagliesi F (2017) Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. Eur J Obstet Gynecol Reproductive Biology 210:157–165

    Google Scholar 

  5. Oyouni AAA (2023) Human papillomavirus in cancer: infection, disease transmission, and progress in vaccines. J Infect Public Health

  6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Meeting, International Agency for Research on Cancer (2007) Human papillomaviruses, vol 90. World Health Organization

  7. Rosário A, Sousa A, Marinho-Dias J, Medeiros R, Lobo C, Leça L, Sousa H (2023) Impact of high‐risk human papillomavirus genotyping in cervical disease in the Northern region of Portugal: real‐world data from regional cervical cancer screening program. J Med Virol 95(1):e28414

    PubMed  Google Scholar 

  8. Ntanasis-Stathopoulos I, Kyriazoglou A, Liontos M, Dimopoulos MA, Gavriatopoulou M (2020) Current trends in the management and prevention of human papillomavirus (HPV) infection. J buon 25(3):1281–1285

    PubMed  Google Scholar 

  9. Szymonowicz KA, Chen J (2020) Biological and clinical aspects of HPV-related cancers. Cancer Biology Med 17(4):864

    CAS  Google Scholar 

  10. Sabatini ME, Chiocca S (2020) Human papillomavirus as a driver of head and neck cancers. Br J Cancer 122(3):306–314

    PubMed  Google Scholar 

  11. Ouh YT, Cho HW, Kim SM, Min KJ, Lee SH, Song JY, Hong JH (2020) Risk factors for type-specific persistence of high-risk human papillomavirus and residual/recurrent cervical intraepithelial neoplasia after surgical treatment. Obstet Gynecol Sci 63(5):631–642

    PubMed  PubMed Central  Google Scholar 

  12. Taku O, Brink A, Meiring TL, Phohlo K, Businge CB, Mbulawa ZZ, Williamson AL (2021) Detection of sexually transmitted pathogens and co-infection with human papillomavirus in women residing in rural Eastern Cape, South Africa. PeerJ 9:e10793

    PubMed  PubMed Central  Google Scholar 

  13. Okunade KS (2020) Human papillomavirus and cervical cancer. J Obstet Gynaecol 40(5):602–608

    CAS  PubMed  Google Scholar 

  14. Albert E, Laimins L (2020) Regulation of the human papillomavirus life cycle by DNA damage repair pathways and epigenetic factors. Viruses 12(7):744

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhang J, Yu G, Yang Y, Wang Y, Guo M, Yin Q, Wang H (2022) A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis. Pharmacol Res 177:106128

    CAS  PubMed  Google Scholar 

  16. Đukić A, Lulić L, Thomas M, Skelin J, Bennett Saidu NE, Grce M, Tomaić V (2020) HPV oncoproteins and the ubiquitin proteasome system: a signature of malignancy? Pathogens 9(2):133

    PubMed  PubMed Central  Google Scholar 

  17. White EA, Sowa ME, Tan MJA, Jeudy S, Hayes SD, Santha S, Howley PM (2012) Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proceedings of the National Academy of Sciences, 109(5), E260-E267

  18. Zhou L (2021) Profiling substrate proteins of Ring and RBR type E3 ligases by Orthogonal Ubiquitin transfer and the development of a peptide activator targeting HECT-type E3 ligase

  19. Sarabia-Vega V, Banks L (2020) Acquisition of a phospho-acceptor site enhances HPV E6 PDZ-binding motif functional promiscuity. J Gen Virol 101(9):954–962

    CAS  PubMed  Google Scholar 

  20. Castaño-Rodriguez C, Honrubia JM, Gutiérrez-Álvarez J, Sola I, Enjuanes L (2021) Viral PDZ binding motifs influence cell behavior through the interaction with cellular proteins containing PDZ domains. PDZ Mediated Interactions: Methods Protocols, 217–236

  21. Đukić A (2023) Interactions of HPV E6 Oncoproteins with Binding Partners: Implications on E6 Stability and Cellular Functions (Doctoral dissertation, University of Rijeka. Department of Biotechnology)

  22. Chen Y, Gu Y, Xiong X, Zheng Y, Liu X, Wang W, Meng G (2022) Roles of the adaptor protein tumor necrosis factor receptor type 1-associated death domain protein (TRADD) in human diseases. Biomed Pharmacother 153:113467

    CAS  PubMed  Google Scholar 

  23. Scarth JA, Patterson MR, Morgan EL, Macdonald A (2021) The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. J Gen Virol, 102(3)

  24. Zou J, Li Y, Chen T, Zhu C (2024) An E7-retinoblastoma protein pathway mechanism may account for the higher carcinogenic ability of HPV16 over HPV58 in cervical cancer. Translational Cancer Res, 13(4)

  25. Pal A, Kundu R (2020) Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol 10:510168

    Google Scholar 

  26. Vats A, Trejo-Cerro O, Thomas M, Banks L (2021) Human papillomavirus E6 and E7: what remains? Tumour Virus Res 11:200213

    PubMed  PubMed Central  Google Scholar 

  27. Mirzaei H, Khodadad N, Karami C, Pirmoradi R, Khanizadeh S (2020) The AP-1 pathway; a key regulator of cellular transformation modulated by oncogenic viruses. Rev Med Virol 30(1):e2088

    PubMed  Google Scholar 

  28. Divya CS, Pillai MR (2006) Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinogenesis: Published Cooperation Univ Tex MD Anderson Cancer Cent 45(5):320–332

    CAS  Google Scholar 

  29. Basukala O, Banks L (2021) The not-so-good, the bad and the ugly: HPV E5, E6 and E7 oncoproteins in the orchestration of carcinogenesis. Viruses 13(10):1892

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Pešut, E., Đukić, A., Lulić, L., Skelin, J., Šimić, I., Milutin Gašperov, N., … Grce,M. (2021). Human papillomaviruses-associated cancers: an update of current knowledge.Viruses, 13(11), 2234

  31. Sadri Nahand, J., Moghoofei, M., Salmaninejad, A., Bahmanpour, Z., Karimzadeh, M.,Nasiri, M., … Hamblin, M. R. (2020). Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review. International journal of cancer, 146(2), 305–320

  32. Shen S, Zhang S, Liu P, Wang J, Du H (2020) Potential role of microRNAs in the treatment and diagnosis of cervical cancer. Cancer Genet 248:25–30

    PubMed  Google Scholar 

  33. Durzynska J, Lesniewicz K, Poreba E (2017) Human papillomaviruses in epigenetic regulations. Mutat Research/Reviews Mutat Res 772:36–50

    CAS  Google Scholar 

  34. Da Silva, M. L. R., De Albuquerque, B. H. D. R., Allyrio, T. A. D. M. F., De Almeida,V. D., Cobucci, R. N. D. O., Bezerra, F. L., … Fernandes, J. V. (2021). The role of HPVinduced epigenetic changes in cervical carcinogenesis. Biomedical Reports, 15(1), 1–20

  35. Sharma S, Munger K (2020) The role of long noncoding RNAs in human papillomavirus-associated pathogenesis. Pathogens 9(4):289

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Jiang M, Liu F, Yang AG, Wang W, Zhang R (2022) The role of long non-coding RNAs in the pathogenesis of head and neck squamous cell carcinoma. Mol Therapy-Oncolytics 24:127–138

    CAS  Google Scholar 

  37. Tornesello, M. L., Faraonio, R., Buonaguro, L., Annunziata, C., Starita, N., Cerasuolo,A., … Buonaguro, F. M. (2020). The role of microRNAs, long non-coding RNAs, and circular RNAs in cervical cancer. Frontiers in oncology, 10, 150

  38. Ding X, Jia X, Wang C, Xu J, Gao SJ, Lu C (2019) A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer. Cell Death Differ 26(9):1750–1765

    CAS  PubMed  Google Scholar 

  39. He H, Liu X, Liu Y, Zhang M, Lai Y, Hao Y, C Zhang T (2019) Human papillomavirus E6/E7 and long noncoding RNA TMPOP2 mutually upregulated gene expression in cervical cancer cells. J Virol 93(8):10–1128

    Google Scholar 

  40. Bonelli P, Borrelli A, Tuccillo FM, Buonaguro FM, Tornesello ML (2021) The role of circRNAs in human papillomavirus (HPV)-associated cancers. Cancers 13(5):1173

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhao, J., Lee, E. E., Kim, J., Yang, R., Chamseddin, B., Ni, C., … Wang, R. C. (2019).Transforming activity of an oncoprotein-encoding circular RNA from human papillomavirus.Nature communications, 10(1), 2300

  42. Stelzle, D., Tanaka, L. F., Lee, K. K., Khalil, A. I., Baussano, I., Shah, A. S.,… Dalal, S. (2021). Estimates of the global burden of cervical cancer associated with HIV. The lancet global health, 9(2), e161-e169

  43. Olusola P, Banerjee HN, Philley JV, Dasgupta S (2019) Human papilloma virus-associated cervical cancer and health disparities. Cells 8(6):622

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Salambanga C, Zohoncon TM, Traoré IMA, Ouedraogo RA, Djigma WF, Ouédraog C, Simpore J (2019) Forte prévalence De L’infection Au Papillomavirus Humain (HPV) à haut risque chez les femmes sexuellement actives dans la ville de Ouagadougou, Burkina Faso. Médecine et SantéTropicales 29(3):302–305

    CAS  Google Scholar 

  45. Nielsen A, Iftner T, Nørgaard M, Munk C, Junge J, Kjaer SK (2012) The importance of low-risk HPV infection for the risk of abnormal cervical cytology/histology in more than 40 000 Danish women. Sex Transm Infect 88(8):627–632

    PubMed  Google Scholar 

  46. Morandell D, Rostek U, Bouvard V, Campo-Fernández B, Fiedler M, Jansen-Dürr P, Zwerschke W (2008) Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression. Virology 379(1):20–29

    CAS  PubMed  Google Scholar 

  47. de Sanjose S, Brotons M, Pavon MA (2018) The natural history of human papillomavirus infection. Best Pract Res Clin Obstet &gynaecology 47:2–13

    Google Scholar 

  48. Bosch FX, De Sanjosé S (2003) Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. JNCI Monogr 2003(31):3–13

    Google Scholar 

  49. Muñoz N (2003) International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527

    PubMed  Google Scholar 

  50. Chen, H. C., Schiffman, M., Lin, C. Y., Pan, M. H., You, S. L., Chuang, L. C., … CBCSP-HPV Study Group. (2011). Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. Journal of the National Cancer Institute, 103(18), 1387–1396

  51. Mbuya, W., Held, K., Mcharo, R. D., Haule, A., Mhizde, J., Mnkai, J., … Geldmacher,C. (2021). Depletion of human papilloma virus E6-and E7-oncoprotein-specific T-cell responses in women living with HIV. Frontiers in Immunology, 4473

  52. Jee B, Yadav R, Pankaj S, Shahi SK (2021) Immunology of HPV-mediated cervical cancer: current understanding. Int Rev Immunol 40(5):359–378

    CAS  PubMed  Google Scholar 

  53. Bhat D (2022) The ‘Why and How’of cervical cancers and genital HPV infection. Cytojournal, 19

  54. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A (2019) Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination—review of current perspectives. Journal of oncology, 2019

  55. Carter SOPHIE, Thurston DE (2020) Immuno-Oncology agents for cancer therapy. Pharm J, 304

  56. Parashar P, Hungyo H, Jain A, Ahmad S, Tandon V (2022) Unraveling molecular mechanisms of head and neck cancer. Crit Rev Oncol/Hematol, 103778

  57. Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14(2):467–475

    CAS  PubMed  Google Scholar 

  58. Evans M, Powell NG (2010) The changing aetiology of head and neck cancer: the role of human papillomavirus. Clin Oncol 22(7):538–546

    CAS  Google Scholar 

  59. Dufour X, Beby-Defaux A, Agius G, Lacau St Guily J (2012) HPV and head and neck cancer. Eur Annals Otorhinolaryngol head neck Dis 129(1):26–31. https://doi.org/10.1016/j.anorl.2011.05.004

    Article  CAS  Google Scholar 

  60. BOSCOLO-RIZZO, P., DEL MISTRO, A., Bussu, F., Lupato, V., Baboci, L., Almadori, G.,… Paludetti, G. (2013). New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta OtorhinolaryngologicaItalica, 33(2), 77

  61. Tumban E (2019) A current update on human papillomavirus-associated head and neck cancers. Viruses 11(10):922

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Goodman, M. T., Saraiya, M., Thompson, T. D., Steinau, M., Hernandez, B. Y., Lynch,C. F., … Unger, E. R. (2015). Human papillomavirus genotype and oropharynx cancer survival in the United States of America. European journal of cancer, 51(18), 2759–2767

  63. Koskinen, W. J., Chen, R. W., Leivo, I., Mäkitie, A., Bäck, L., Kontio, R., … Aaltonen,L. M. (2003). Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. International journal of cancer, 107(3), 401–406

  64. Chaturvedi AK, Engels EA, Anderson WF, &Gillison ML (2008) Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26(4):612–619

    PubMed  Google Scholar 

  65. Deng, Z., Hasegawa, M., Yamashita, Y., Matayoshi, S., Kiyuna, A., Agena, S., … Suzuki,M. (2012). Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer science, 103(12), 2127–2134

  66. Gillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein,D. J., … Le, Q. T. (2019). Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet, 393(10166), 40–50

  67. Haeggblom L, Ramqvist T, Tommasino M, Dalianis T, Näsman A (2017) Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years. Papillomavirus Res 4:1–11

    PubMed  PubMed Central  Google Scholar 

  68. Marklund, L., Holzhauser, S., de Flon, C., Zupancic, M., Landin, D., Kolev, A., …Näsman, A. (2020). Survival of patients with oropharyngeal squamous cell carcinomas(OPSCC) in relation to TNM 8–risk of incorrect downstaging of HPV-mediated non-tonsillar,non-base of tongue carcinomas. European Journal of Cancer, 139, 192–200

  69. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92(9):709–720. https://doi.org/10.1093/jnci/92.9.709

    Article  CAS  PubMed  Google Scholar 

  70. Hennessey PT, Westra WH, Califano JA (2009) Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implications. J Dent Res 88(4):300–306

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Economopoulou P, Kotsantis I, Psyrri A (2020) Special issue about head and neck cancers: HPV positive cancers. Int J Mol Sci 21(9):3388

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Masterson, L., Moualed, D., Liu, Z. W., Howard, J. E., Dwivedi, R. C., Tysome, J.R., … Goon, P. K. (2014). De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. European journal of cancer, 50(15), 2636–2648

  73. Gleber-Netto, F. O., Rao, X., Guo, T., Xi, Y., Gao, M., Shen, L., … Pickering, C.R. (2019). Variations in HPV function are associated with survival in squamous cell carcinoma. JCI insight, 4(1)

  74. Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R.J., … Myers, J. N. (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science, 333(6046), 1154–1157

  75. Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko,A., … Grandis, J. R. (2011). The mutational landscape of head and neck squamous cell carcinoma. Science, 333(6046), 1157–1160

  76. Piipponen M, Riihilä P, Nissinen L, Kähäri VM (2021) The role of p53 in progression of cutaneous squamous cell carcinoma. Cancers 13(18):4507

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Aguayo, F., Muñoz, J. P., Perez-Dominguez, F., Carrillo-Beltrán, D., Oliva, C., Calaf,G. M., … Nuñez-Acurio, D. (2020). High-risk human papillomavirus and tobacco smoke interactions in epithelial carcinogenesis. Cancers, 12(8), 2201

  78. Bossart, S., Daneluzzi, C., Moor, M. B., Hirzel, C., Heidemeyer, K., Seyed Jafari,S. M., … Sidler, D. (2023). HPV Vaccination in immunosuppressed patients with established skin warts and non-melanoma skin cancer: A single-institutional cohort study. Vaccines, 11(9), 1490

  79. Gheit T (2019) Mucosal and cutaneous human papillomavirus infections and cancer biology. Front Oncol 9:355

    PubMed  PubMed Central  Google Scholar 

  80. Baez, C. F., Gonçalves, M. T. V., da Rocha, W. M., Magalhães de Souza, L., Savassi-Ribas,F., de Oliveira Almeida, N. K., … Varella, R. B. (2019). Investigation of three oncogenic epitheliotropic viruses shows human papillomavirus in association with non-melanoma skin cancer. European Journal of Clinical Microbiology & Infectious Diseases, 38, 1129–1133

  81. Chen ML, Wang SH, Wei JCC, Yip HT, Hung YM, Chang R (2021) The impact of human papillomavirus infection on skin Cancer: a Population-based Cohort Study. Oncologist 26(3):e473–e483

    CAS  PubMed  Google Scholar 

  82. Martínez-Bailón, C., Mantilla-Morales, A., Méndez-Matías, G., Alvarado-Cabrero, I.,Maldonado-Rodríguez, R., Quintero-Becerra, J., … Piña-Sánchez, P. (2019). Human papillomavirus genotypes and P16INK4A expression in squamous penile carcinoma in Mexican patients.BMC Infectious Diseases, 19(1), 1–8

  83. Akgül B, Lemme W, Garcia-Escudero R, Storey A, Pfister HJ (2005) UV-B irradiation stimulates the promoter activity of the high-risk, cutaneous human papillomavirus 5 and 8 in primary keratinocytes. Arch Virol 150:145–151

    PubMed  Google Scholar 

  84. Maréchal A, Zou L (2013) DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 5(9):a012716

    PubMed  PubMed Central  Google Scholar 

  85. O’Connor MJ (2015) Targeting the DNA damage response in cancer. Mol Cell 60(4):547–560

    PubMed  Google Scholar 

  86. Hufbauer M, Cooke J, van der Horst GT, Pfister H, Storey A, Akgül B (2015) Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis. Mol Cancer 14(1):1–12

    Google Scholar 

  87. Blackford AN, Jackson SP (2017) ATM, ATR, and DNA-PK: the Trinity at the heart of the DNA damage response. Mol Cell 66(6):801–817

    CAS  PubMed  Google Scholar 

  88. Snow JA, Murthy V, Dacus D, Hu C, Wallace NA (2019) β-HPV 8E6 attenuates ATM and ATR Signaling in response to UV damage. Pathogens 8(4):267

    CAS  PubMed  PubMed Central  Google Scholar 

  89. hui Xu H, Lin A, hong Chen Y, Dong shan, Shi S, Yu Wzheng, J., &hua, Yan W (2017) Prevalence characteristics of cervical human papillomavirus (HPV) genotypes in the Taizhou area, China: a cross-sectional study of 37 967 women from the general population. BMJ open, 7(6), e014135

  90. Boon SS, Chen Z, Li J, Lee KY, Cai L, Zhong R, Chan PK (2019) Human papillomavirus type 18 oncoproteins exert their oncogenicity in esophageal and tongue squamous cell carcinoma cell lines distinctly. BMC Cancer 19(1):1–12

    Google Scholar 

  91. Wang Y, Zeng G, Jiang Y (2020) The emerging roles of miR-125b in cancers. Cancer Manage Res 12:1079

    CAS  Google Scholar 

  92. Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 28(10):1563–1579

    PubMed  PubMed Central  Google Scholar 

  93. Huang JY, Lin C, Tsai SCS, Lin FCF (2022) Human papillomavirus is associated with adenocarcinoma of lung: a population-based cohort study. Front Med 9:932196

    Google Scholar 

  94. Karnosky, J., Dietmaier, W., Knuettel, H., Freigang, V., Koch, M., Koll, F., … Schulz,C. (2021). HPV and lung cancer: A systematic review and meta-analysis. Cancer Reports, 4(4), e1350

  95. Budisan, L., Zanoaga, O., Braicu, C., Pirlog, R., Covaliu, B., Esanu, V., … Berindan-Neagoe,I. (2021). Links between infections, lung cancer, and the immune system. International journal of molecular sciences, 22(17), 9394

  96. Malhone C, Longatto-Filho A, Filassi JR (2018) Is human papilloma virus associated with breast cancer? A review of the molecular evidence. Acta Cytol 62(3):166–177

    PubMed  Google Scholar 

  97. Sigaroodi A, Nadji SA, Naghshvar F, Nategh R, Emami H, Velayati AA (2012) Human papillomavirus is associated with breast cancer in the north part of Iran. The Scientific World Journal, 2012

  98. Stuebs, F. A., Gass, P., Dietl, A. K., Schulmeyer, C. E., Adler, W., Geppert, C.,… Koch, M. C. (2021). Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix. Archives of Gynecology and Obstetrics, 304, 751–758

  99. Gupta I, Ulamec M, Peric-Balja M, Ramic S, Al Moustafa AE, Vranic S, Al-Farsi HF (2021) Presence of high-risk HPVs, EBV, and MMTV in human triple-negative breast cancer. Hum Vaccines &Immunotherapeutics 17(11):4457–4466

    CAS  Google Scholar 

  100. Blanco R, Carrillo-Beltrán D, Muñoz JP, Corvalán AH, Calaf GM, Aguayo F (2021) Human papillomavirus in breast carcinogenesis: a passenger, a cofactor, or a causal agent? Biology 10(8):804

    PubMed  PubMed Central  Google Scholar 

  101. Gannon OM, Antonsson A, Milevskiy M, Brown MA, Saunders NA, Bennett IC (2015) No association between HPV positive breast cancer and expression of human papilloma viral transcripts. Sci Rep 5(1):18081

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Doosti M, Bakhshesh M, Zahir ST, Shayestehpour M, Karimi-Zarchi M (2016) Lack of evidence for a relationship between high risk human papillomaviruses and breast cancer in Iranian patients. Asian Pac J Cancer Prev 17(9):4357–4361

    PubMed  Google Scholar 

  103. Bakhtiyrizadeh S, Hosseini SY, Yaghobi R, Safaei A, Sarvari J (2017) Almost complete lack of human cytomegalovirus and human papillomaviruses genome in benign and malignant breast lesions in Shiraz, Southwest of Iran. Asian Pac J cancer Prevention: APJCP 18(12):3319

    Google Scholar 

  104. Cavalcante, J. R., Pinheiro, L. G. P., Almeida, P. R. C. D., Ferreira, M. V. P., Cruz,G. A., Campelo, T. A., … Frota, C. C. (2018). Association of breast cancer with human papillomavirus (HPV) infection in Northeast Brazil: molecular evidence. Clinics, 73

  105. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118(12):3030–3044

    CAS  PubMed  Google Scholar 

  106. Morris, V. K., Rashid, A., Rodriguez-Bigas, M., Das, P., Chang, G., Ohinata, A., …Eng, C. (2015). Clinicopathologic features associated with human papillomavirus/p16 in patients with metastatic squamous cell carcinoma of the anal canal. The oncologist, 20(11), 1247–1252

  107. Baricevic, I., He, X., Chakrabarty, B., Oliver, A. W., Bailey, C., Summers, J., …Renehan, A. G. (2015). High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. European journal of cancer, 51(6), 776–785

  108. Hillman, R. J., Garland, S. M., Gunathilake, M. P., Stevens, M., Kumaradevan, N.,Lemech, C., … Tabrizi, S. N. (2014). Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. International journal of cancer, 135(4), 996–1001

  109. Stier EA, Chigurupati NL, Fung L (2016) Prophylactic HPV vaccination and anal cancer. Hum Vaccines &immunotherapeutics 12(6):1348–1351

    Google Scholar 

  110. Yhim, H. Y., Lee, N. R., Song, E. K., Kwak, J. Y., Lee, S. T., Kim, J. H., … Yim,C. Y. (2011). The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy.International journal of cancer, 129(7), 1752–1760

  111. Harima Y, Sawada S, Nagata K, Sougawa M, Ohnishi T (2002) Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. Int J Radiation Oncology* Biology* Phys 52(5):1345–1351

    CAS  Google Scholar 

  112. Meulendijks, D., Tomasoa, N. B., Dewit, L., Smits, P. H. M., Bakker, R., Van Velthuysen,M. L., … Cats, A. (2015). HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. British journal of cancer, 112(8), 1358–1366

  113. Nelson RA, Lai LL (2017) Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer. Cancer 123(20):4013–4021

    PubMed  Google Scholar 

  114. Merlo AS (2020) Modern treatment of vulvar cancer. Radiol Oncol 54(4):371

    PubMed  PubMed Central  Google Scholar 

  115. Kortekaas, K. E., Bastiaannet, E., van Doorn, H. C., van Steenwijk, P. J. D. V., Ewing-Graham,P. C., Creutzberg, C. L., … van Poelgeest, M. I. (2020). Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecologic Oncology, 159(3), 649–656

  116. Rafael, T. S., Rotman, J., Brouwer, O. R., van der Poel, H. G., Mom, C. H., Kenter,G. G., … Jordanova, E. S. (2022). Immunotherapeutic approaches for the treatment of HPV-associated (Pre-) Cancer of the cervix, vulva and penis. Journal of Clinical Medicine, 11(4), 1101

  117. Yu YB, Wang YH, Yang XC, Zhao Y, Wang ML, Liang Y, Niu HT (2019) The relationship between human papillomavirus and penile cancer over the past decade: a systematic review and meta-analysis. Asian J Androl 21(4):375

    PubMed  PubMed Central  Google Scholar 

  118. Schlenker B, Schneede P (2019) The role of human papilloma virus in penile cancer prevention and new therapeutic agents. Eur Urol Focus 5(1):42–45

    PubMed  Google Scholar 

  119. Thomas A, Necchi A, Muneer A, Tobias-Machado M, Tran ATH, Van Rompuy AS, Albersen M (2021) Penile cancer. Nat Reviews Disease Primers 7(1):11

    PubMed  Google Scholar 

  120. Vanthoor J, Vos G, Albersen M (2021) Penile cancer: potential target for immunotherapy? World J Urol 39:1405–1411

    PubMed  Google Scholar 

  121. Albuquerque, K. S., Zoghbi, K. K., Gomes, N. B. N., Libânio, B. B., Souza, T. X.,de Araújo, E. M., … Bernardo, G. C. O. (2022). Vaginal cancer: Why should we care?Anatomy, staging and in-depth imaging-based review of vaginal malignancies focusing on MRI and PET/CT. Clinical Imaging, 84, 65–78

  122. Männle H, Osorio B, Momm F, Münstedt K (2021) Is there an Association between Vaginal Cancer and Genital Prolapse? A Data-Analysis and Review of Literature. Int J Oncol Res 4:027

    Google Scholar 

  123. Bertoli HK, Rasmussen CL, Sand FL, Albieri V, Norrild B, Verdoodt F, Kjaer SK (2019) Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina. Int J Cancer 145(1):78–86

    CAS  PubMed  Google Scholar 

  124. Salama AM, Momeni-Boroujeni A, Vanderbilt C, Ladanyi M, Soslow R (2022) Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma. Mod Pathol 35(2):274–282

    CAS  PubMed  Google Scholar 

  125. Dasgupta S (2023) The efficiency of cervical pap and comparison of conventional pap smear and liquid-based cytology: a review. Cureus, 15(11)

  126. Hirsch, B. E., McGowan, J. P., Fine, S. M., Vail, R., Merrick, S. T., Radix, A., …Gonzalez, C. J. (2020). Screening for Anal Dysplasia and Cancer in Adults With HIV

  127. Sachan PL, Singh M, Patel ML, Sachan R (2018) A study on cervical cancer screening using pap smear test and clinical correlation. Asia-Pacific J Oncol Nurs 5(3):337–341

    Google Scholar 

  128. Chandran, V., Sumithra, M. G., Karthick, A., George, T., Deivakani, M., Elakkiya,B., … Manoharan, S. (2021). Diagnosis of cervical cancer based on ensemble deep learning network using colposcopy images. BioMed Research International, 2021

  129. Gudur A, Shanmuganandamurthy D, Szep Z, Poggio JL (2019) An update on the current role of high resolution Anoscopy in patients with anal dysplasia. Anticancer Res 39(1):17–23

    CAS  PubMed  Google Scholar 

  130. Bhatla, N., Singhal, S., Saraiya, U., Srivastava, S., Bhalerao, S., Shamsunder, S.,… Zutshi, V. (2020). Screening and management of preinvasive lesions of the cervix:Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI). Journal of Obstetrics and Gynaecology Research, 46(2), 201–214

  131. Staples JN, Duska LR (2019) Cancer screening and prevention highlights in gynecologic cancer. Obstet Gynecol Clin 46(1):19–36

    Google Scholar 

  132. Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG (2019) HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Human vaccines &immunotherapeutics

  133. Simoens, C., Gheit, T., Ridder, R., Gorbaslieva, I., Holzinger, D., Lucas, E., … Arbyn,M. (2022). Accuracy of high-risk HPV DNA PCR, p16 (INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer. BMC Infectious Diseases, 22(1), 676

  134. Lifsics A, Cistjakovs M, Sokolovska L, Deksnis R, Murovska M, Groma V (2023) The role of the p16 and p53 tumor suppressor proteins and viral HPV16 E6 and E7 oncoproteins in the Assessment of Survival in patients with Head and Neck Cancers Associated with Human Papillomavirus infections. Cancers 15(10):2722

    CAS  PubMed  PubMed Central  Google Scholar 

  135. da Mata, S., Ferreira, J., Nicolás, I., Esteves, S., Esteves, G., Lérias, S., … Félix,A. (2021). P16 and HPV genotype significance in HPV-associated cervical cancer—a large cohort of two tertiary referral centers. International Journal of Molecular Sciences, 22(5), 2294

  136. Chahoud, J., Zacharias, N. M., Pham, R., Qiao, W., Guo, M., Lu, X., … Pettaway, C.A. (2022). Prognostic Significance of p16 and Its Relationship with Human Papillomavirus Status in Patients with Penile Squamous Cell Carcinoma: Results of 5 Years Follow-Up.Cancers, 14(24), 6024

  137. Devine C, Viswanathan C, Faria S, Marcal L, Sagebiel TL (2019) August). Imaging and staging of cervical cancer. Seminars in Ultrasound, CT and MRI, vol 40. WB Saunders, pp 280–286. 4

  138. Morgan RL, Eguchi MM, Mueller AC, Daugherty SL, Amini A, Karam SD (2019) Imaging at diagnosis impacts cancer-specific survival among patients with cancer of the oropharynx. Cancer 125(16):2794–2802

    CAS  PubMed  Google Scholar 

  139. Hakenberg OW, Dräger DL, Erbersdobler A, Naumann CM, Jünemann KP, Protzel C (2018) The diagnosis and treatment of penile cancer. DeutschesÄrzteblatt Int 115(39):646

    Google Scholar 

  140. Athanasiou A, Bowden S, Paraskevaidi M, Fotopoulou C, Martin-Hirsch P, Paraskevaidis E, Kyrgiou M (2020) HPV vaccination and cancer prevention. Best Pract Res Clin Obstet &Gynaecology 65:109–124

    CAS  Google Scholar 

  141. Enríquez-Aceves I, Galicia-Carmona T, Coronel-Martínez JA, Espinosa-Romero R, Calderillo-Ruíz G, Cortés-Esteban P (2020) &Cetina-Pérez, L. Standard treatment with bevacizumab as targeted therapy in cervical cancer. Revista de investigaciónclínica, 72(4), 213–218

  142. Lee EK, Konstantinopoulos PA (2020) PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. Therapeutic Adv Med Oncol 12:1758835920944116

    CAS  Google Scholar 

  143. Chu E (2016) Physicians’ Cancer Chemotherapy Drug Manual 2017. Jones & Bartlett Learning

  144. Arrieta O, Lara-Mejía L, Zatarain-Barrón ZL (2020) Carboplatin plus etoposide or topotecan for small-cell lung cancer. Lancet Oncol 21(9):1132–1134

    CAS  PubMed  Google Scholar 

  145. Alsahafi EN, Thavaraj S, Sarvestani N, Novoplansky O, Elkabets M, Ayaz B, Tavassoli M (2021) EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation. Cancer Lett 498:80–97

    CAS  PubMed  Google Scholar 

  146. Alken S, Kelly CM (2013) Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manage Res, 357–365

  147. Chan ES, Cronstein BN (2013) Mechanisms of action of methotrexate. Bull NYU Hosp Joint Dis 71(suppl 1):S5

    Google Scholar 

  148. Altinoz MA, Ozpinar A, Alturfan EE, Elmaci I (2018) Vinorelbine’s anti-tumor actions may depend on the mitotic apoptosis, autophagy and inflammation: hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas. J Chemother 30(4):203–212

    CAS  PubMed  Google Scholar 

  149. Wilson KC, Flood MP, Oh D, Calvin N, Michael M, Ramsay RG, Heriot AG (2021) Immune checkpoint blockade in lower gastrointestinal cancers: a systematic review. Ann Surg Oncol 28(12):7463–7473

    CAS  PubMed  Google Scholar 

  150. Nie, D., Wang, X., Sun, M., Feng, Z., Pei, F., Liu, W., … Han, F. (2021). The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors:A systematic review and meta-analysis. Radiotherapy and Oncology, 158, 13–20

  151. Ferrando-Díez A, Pavón MA, Cirauqui B, Alemany L, Mesía R (2023) How to prevent human papillomavirus-related oropharyngeal cancer? Curr Opin Oncol 35(3):145–150

    PubMed  Google Scholar 

  152. Koshiyama M (2019, July) The effects of the dietary and nutrient intake on gynecologic cancers. Healthcare, vol 7. MDPI, p 88. 3

  153. Das BC, Hussain S, Nasare V, Bharadwaj M (2008) Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 26(22):2669–2679

    PubMed  Google Scholar 

  154. Gupta S, Kumar P, Das BC (2023) Challenges and opportunities to making Indian women cervical cancer free. Indian J Med Res 158(56):470–475

    CAS  PubMed  Google Scholar 

  155. Jayraj AS, Singhal S (2024) The beginning of the end for cervical cancer in India. Int J Gynecologic Cancer, ijgc-2024.

  156. Joura, E. A., Ulied, A., Vandermeulen, C., Figueroa, M. R., Seppä, I., Aguado, J.J. H., … Wittke, F. (2021). Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study. Vaccine, 39(20), 2800–2809

  157. Ersado TL (2021) Cervical Cancer Prevention and Control. In Cervical Cancer-A Global Public Health Treatise. IntechOpen.Wipperman, J., Neil, T., &Williams, T. (2018). Cervical cancer: evaluation and management. American family physician, 97(7), 449–454

  158. Markowitz LE, Schiller JT (2021) Human papillomavirus vaccines. J Infect Dis 224(Supplement4):S367–S378

    CAS  PubMed  PubMed Central  Google Scholar 

  159. Sharma, H., Parekh, S., Pujari, P., Shewale, S., Desai, S., Bhatla, N., … Shaligram,U. (2023). Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.The Lancet Oncology, 24(12), 1321–1333

  160. Dwivedi P, Lahariya AU, Pandey S, Sreedevi A, Lohiya A, Lahariya C (2024) Cervical Cancer and human papilloma virus (HPV) vaccines: a primer for General Physicians. Prev Medicine: Res Reviews, 10–4103

  161. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N (2017) Cervical cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv72–iv83

    CAS  PubMed  Google Scholar 

  162. Ertem G, Hazar S (2022) Symptom management and Nursing Care in Palliative Care of Cervical Cancer patients. J Educ Res Nurs 19(2):262–268

    Google Scholar 

  163. Somigliana, E., Mangili, G., Martinelli, F., Noli, S., Filippi, F., Bergamini, A.,… Peccatori, F. (2020). Fertility preservation in women with cervical cancer. Critical Reviews in Oncology/Hematology, 154, 103092

  164. Chao X, Fan J, Song X, You Y, Wu H, Wu M, Li L (2020) Diagnostic strategies for recurrent cervical cancer: a cohort study. Front Oncol 10:591253

    PubMed  PubMed Central  Google Scholar 

  165. Lee S, Rajeev P, Finning S, Oh C, Pothuri B (2022) Factors associated with delayed genetic testing for patients with BRCA-related cancers (428). Gynecol Oncol 166:S215–S216

    Google Scholar 

  166. Taghizadeh, H., Mader, R. M., Müllauer, L., Aust, S., Polterauer, S., Kölbl, H., …Prager, G. W. (2020). Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform. The Oncologist, 25(7), e1060-e1069

  167. Chabeda A, Yanez RJ, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II (2018) Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res 5:46–58

    PubMed  Google Scholar 

  168. Malik S, Sah R, Muhammad K, Waheed Y (2023) Tracking HPV infection, Associated Cancer Development, and recent treatment Efforts—A Comprehensive Review. Vaccines 11(1):102

    CAS  PubMed  PubMed Central  Google Scholar 

  169. Khan, A. Q., Rashid, K., AlAmodi, A. A., Agha, M. V., Akhtar, S., Hakeem, I., … Uddin,S. (2021). Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids. Biomedicine & Pharmacotherapy, 143, 112142

  170. Pourhanifeh, M. H., Darvish, M., Tabatabaeian, J., Fard, M. R., Mottaghi, R., Azadchehr,M. J., … Mirzaei, H. (2020). Therapeutic role of curcumin and its novel formulations in gynecological cancers. Journal of Ovarian Research, 13(1), 1–16

  171. Ratheesh M, Jose SP, Krishnakumar IM, Sandya S, Saji S, Sheethal S (2021) Curcumin-galactomannoside complex inhibits the proliferation of human cervical cancer cells: possible role in cell cycle arrest and apoptosis. Asian Pac J Cancer Prevention: APJCP 22(6):1713

    Google Scholar 

  172. Sadeghi RV, Parsania M, Sadeghizadeh M, Haghighat S, Farsani SSM (2021) The comparison of curcumin and nanocurcumin effects on the expression of E6 and E7 human papilloma virus oncogenes and P53 and pRb factors in HeLa and fibroblast cell lines

  173. Sabanayagam R, Krishnamoorthy S, Gnanagurusamy J, Muruganatham B, Muthusami S (2023) EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells. Med Oncol 40(9):261

    CAS  PubMed  Google Scholar 

  174. Tang, Y., Chen, Q., Chen, J., Mo, Z., Li, H., Peng, L., … Zhu, H. (2022). Green tea polyphenols cause apoptosis and autophagy in HPV-16 subgene-immortalized human cervical epithelial cells via the activation of the Nrf2 pathway. Nutrition and Cancer, 74(10), 3769–3778

  175. Shafabakhsh R, Reiter RJ, Aschner M, Mirzaei H, Asemi Z (2023) Resveratrol and cervical cancer: a new therapeutic option. Mini Rev Med Chem 23(2):159–169

    CAS  PubMed  Google Scholar 

  176. Massa S, Pagliarello R, Paolini F, Venuti A (2022) Natural bioactives: back to the future in the fight against human papillomavirus? A narrative review. J Clin Med 11(5):1465

    CAS  PubMed  PubMed Central  Google Scholar 

  177. Kharaeva, Z., Trakhtman, P., Trakhtman, I., De Luca, C., Mayer, W., Chung, J., … Korkina,L. (2022). Fermented Mangosteen (Garcinia mangostana L.) Supplementation in the Prevention of HPV-Induced Cervical Cancer: From Mechanisms to Clinical Outcomes. Cancers, 14(19), 4707

  178. Ferreira M, Gomes D, Neto M, Passarinha LA, Costa D, Sousa  (2023) Development and characterization of quercetin-loaded Delivery systems for increasing its bioavailability in Cervical Cancer cells. Pharmaceutics 15(3):936

    CAS  PubMed  PubMed Central  Google Scholar 

  179. Franconi R, Massa S, Paolini F, Vici P, Venuti A (2020) Plant-derived natural compounds in genetic vaccination and therapy for HPV-associated cancers. Cancers 12(11):3101

    CAS  PubMed  PubMed Central  Google Scholar 

  180. Woźniak M, Krajewski R, Makuch S, Agrawal S (2021) Phytochemicals in gynecological cancer prevention. Int J Mol Sci 22(3):1219

    PubMed  PubMed Central  Google Scholar 

  181. Yan-Hua YANG, Jia-Wang MAO, Xiao-Li TAN (2020) Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. Chin J Nat Med 18(12):890–897

    Google Scholar 

  182. Alavi M, Nokhodchi A (2022) Micro-and nanoformulations of paclitaxel based on micelles, liposomes, cubosomes, and lipid nanoparticles: recent advances and challenges. Drug Discovery Today 27(2):576–584

    CAS  PubMed  Google Scholar 

  183. Singh, T., Chhokar, A., Thakur, K., Aggarwal, N., Pragya, P., Yadav, J., … Chandra Bharti, A. (2021). Targeting aberrant expression of STAT3 and AP-1 oncogenic transcription factors and HPV oncoproteins in cervical cancer by Berberis aquifolium. Frontiers in Pharmacology, 12, 757414

  184. Garcia-Becerra N, Aguilar-Lemarroy A, Jave-Suárez LF (2023) On the regulation of NF-κB pathway by HPV oncoproteins: are pathway inhibitors a good Alternative for the treatment of Cervical Cancer? Anti-Cancer Agents Med Chem (Formerly Curr Med Chemistry-Anti-Cancer Agents) 23(5):492–497

    CAS  Google Scholar 

  185. Aghamiri, S., Talaei, S., Roshanzamiri, S., Zandsalimi, F., Fazeli, E., Aliyu, M.,… Ghanbarian, H. (2020). Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy. Expert opinion on drug delivery, 17(6), 753–766.Sabatini, M. E., &Chiocca, S. (2020). Human papillomavirus as a driver of head and neck cancers. British journal of cancer, 122(3), 306–314

  186. Yili FENG, Sicheng LIU, Ruodan CHEN, Anyong XIE (2021) Target binding and residence: a new determinant of DNA double-strand break repair pathway choice in CRISPR/Cas9 genome editing. J Zhejiang Univ Sci B 22(1):73

    Google Scholar 

  187. Gupta RM, Musunuru K (2014) Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Investig 124(10):4154–4161

    PubMed  PubMed Central  Google Scholar 

  188. Inturiet R, Jemth P (2021) CRISPR/Cas9-based inactivation of human papillomavirus oncogenes E6 or E7 induces senescence in cervical cancer cells. Virology 562:92–102

    Google Scholar 

  189. Jubair L, Fallaha S, McMillan NA (2019) Systemic delivery of CRISPR/Cas9 targeting HPV oncogenes is effective at eliminating established tumors. Mol Ther 27(12):2091–2099

    CAS  PubMed  PubMed Central  Google Scholar 

  190. Yoshiba T, Saga Y, Urabe M, Uchibor R, Matsubara S, Fujiwara H, Mizukami H (2019) CRISPR/Cas9mediated cervical cancer treatment targeting human papillomavirus E6. Oncol Lett 17(2):2197–2206

    CAS  PubMed  Google Scholar 

  191. Ling, K., Yang, L., Yang, N., Chen, M., Wang, Y., Liang, S., … Liang, Z. (2020). Gene targeting of HPV18 E6 and E7 synchronously by nonviral transfection of CRISPR/Cas9 system in cervical cancer. Human gene therapy, 31(5–6), 297–308

  192. Xu W, Jiang X, Huang L (2019) RNA interference technology. Compr Biotechnol, 560

  193. Gao, C., Wu, P., Yu, L., Liu, L., Liu, H., Tan, X., … Wang, H. (2022). The application of CRISPR/Cas9 system in cervical carcinogenesis. Cancer Gene Therapy, 29(5), 466–474

  194. Zhen S, Lu J, Liu YH, Chen W, Li X (2020) Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout. Cancer Gene Ther 27(3):168–178

    CAS  PubMed  Google Scholar 

  195. Zhen, S., Chen, H., Lu, J., Yang, X., Tuo, X., Chang, S., … Li, X. (2023). Intravaginal delivery for CRISPR–Cas9 technology: For example, the treatment of HPV infection.Journal of Medical Virology, 95(2), e28552

  196. Kara G, Calin GA, Ozpolat B (2022) RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev, 114113

  197. Kampel, L., Goldsmith, M., Ramishetti, S., Veiga, N., Rosenblum, D., Gutkin, A., …Muhanna, N. (2021). Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles. Journal of Controlled Release, 337, 378–389

  198. Sato, N., Saga, Y., Uchibori, R., Tsukahara, T., Urabe, M., Kume, A., … Mizukami,H. (2018). Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7. International Journal of Oncology, 52(3), 687–696

  199. Scott-Wittenborn N, Fakhry C (2021) October). Epidemiology of HPV related malignancies. Seminars in Radiation Oncology, vol 31. WB Saunders, pp 286–296. 4

  200. Youn, J. W., Hur, S. Y., Woo, J. W., Kim, Y. M., Lim, M. C., Park, S. Y., … Sung,Y. C. (2020). Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. The Lancet Oncology, 21(12), 1653–1660

  201. Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, Petit R (2018) A randomized phase 2 study of ADXS11-001 Listeria monocytogenes–listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer 28(4):764

    PubMed  PubMed Central  Google Scholar 

  202. Eng C, Fakih M, Amin M, Morris V, Hochster HS, Boland PM, Uronis H (2020) A phase II study of axalimogenefilolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget 11(15):1334

    PubMed  PubMed Central  Google Scholar 

  203. Hasan, Y., Furtado, L., Tergas, A., Lee, N., Brooks, R., McCall, A., … Spiotto, M.(2020). A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. International Journal of Radiation Oncology* Biology* Physics, 107(3), 487–498

  204. Huh, W. K., Brady, W. E., Fracasso, P. M., Dizon, D. S., Powell, M. A., Monk, B. J.,… Aghajanian, C. (2020). Phase II study of axalimogenefilolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. Gynecologic oncology, 158(3), 562–569

  205. Safran, H., Leonard, K. L., Perez, K., Vrees, M., Klipfel, A., Schechter, S., … DiPetrillo,T. A. (2018). Tolerability of ADXS11-001 Lm-LLO Listeria-based immunotherapy with mitomycin, fluorouracil, and radiation for anal cancer. International Journal of Radiation Oncology* Biology* Physics, 100(5), 1175–1178

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Genetics, Maharshi Dayanand University, Rohtak, Haryana, 124001, India

    Nikita Balhara, Ritu Yadav, Shalu Ranga, Parul Ahuja & Mukesh Tanwar

Authors
  1. Nikita Balhara
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Ritu Yadav
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Shalu Ranga
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Parul Ahuja
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Mukesh Tanwar
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

The authors declare that they have no competing interests.

Corresponding author

Correspondence to Ritu Yadav.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Consent to publish

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balhara, N., Yadav, R., Ranga, S. et al. Understanding the HPV associated cancers: A comprehensive review. Mol Biol Rep 51, 743 (2024). https://doi.org/10.1007/s11033-024-09680-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11033-024-09680-6

Keywords









 ApplySandwichStrip

pFad - (p)hone/(F)rame/(a)nonymizer/(d)eclutterfier!      Saves Data!


--- a PPN by Garber Painting Akron. With Image Size Reduction included!

Fetched URL: https://link.springer.com/10.1007/s11033-024-09680-6

Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy